CSIMarket Company Name, Ticker, Suppliers, else..
 
Autolus Therapeutics Plc  (NASDAQ: AUTL)
 
Price: $2.2600 $-0.03 -1.310%
Day's High: $2.299999952316284 Week Perf: -3.83 %
Day's Low: $ 2.25 30 Day Perf: 13 %
Volume (M): 331,328 52 Wk High: $ 2.58
Volume (M$): $ 0 52 Wk Avg: $1.60
Open: $2.29 52 Wk Low: $1.17



 Market Capitalization (Millions $) 602
 Shares Outstanding (Millions) 266
 Employees 754
 Revenues (TTM) (Millions $) 117
 Net Income (TTM) (Millions $) -280
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 58

Business Description


Autolus Therapeutics Plc is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation, programmed T-cell therapies for the treatment of cancer. They utilize their proprietary technology to engineer cell therapies with improved safety and efficacy compared to traditional approaches. Autolus is known for its innovative approach to developing personalized therapies that target and destroy cancer cells, while leaving healthy cells intact. The company's pipeline includes a range of product candidates targeting various types of blood cancers, including B-cell malignancies and multiple myeloma. Autolus Therapeutics aims to revolutionize cancer treatment by harnessing the power of the immune system to effectively and selectively eliminate cancer cells.


   Company Address: The Mediaworks London 0
   Company Phone Number: 3829 6230   Stock Exchange / Ticker: NASDAQ AUTL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGEN        6.27% 
BEAM        1.07% 
CCCC   -4.03%    
LENZ        10.67% 
MRNA        5.82% 
TCRX   -50%    
• View Complete Report
   



Product Service News

Breakthrough FDA Approval for Obecabtagene Autoleucel A New Horizon in Treatment for Relapsed/Refractory B-Cell Acute...

Published Fri, Nov 8 2024 9:24 PM UTC

Autolus Therapeutics has recently announced the FDA approval of AUCATZYL (obecabtagene autoleucel or obe-cel) for the treatment of adults suffering from relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This pivotal decision follows a recognized need for more effective treatment options for a patient population with historically poor prognosis. The a...
Clinical Study

Autolus Therapeutics to Illuminate Hematologic Cancer Treatment with Key Clinical Updates at ASH 2024,

Published Tue, Nov 5 2024 2:01 PM UTC

The Future of CAR T-Cell Therapy: Autolus Therapeutics Showcases Promising Data at the 2024 ASH Annual Meeting Autolus Therapeutics, a pioneering organization in the realm of next-generation T-cell therapies, continues to push the boundaries of innovation in the treatment of hematological cancers. As it gears up to present pivotal clinical data updates during the esteemed Am...
Clinical Study

Advancing Therapies Amid Financial Headwinds Clinical and Economic Update for Autolus Therapeutics at SOHO 2024,

Published Tue, Aug 27 2024 11:00 AM UTC

Clinical and Financial Update on Autolus Therapeutics at the 2024 SOHO Annual MeetingAutolus Therapeutics Plc, a clinical-stage biopharmaceutical company dedicated to the development of next-generation programmed T cell therapies for the treatment of cancer, recently presented significant clinical data updates at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024...
Clinical Study

Extended Analysis of Autolus Therapeutics Obe-cel Study Reveals Promising Outcomes for...

Published Fri, May 31 2024 12:00 PM UTC

In the realm of cancer therapeutics, Autolus Therapeutics has recently presented intriguing new data from their Pivotal Phase 2 FELIX study of obe-cel (formerly known as AUTO1) for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This article aims to outline the key findings and discuss their potential impact on the company s future...
Clinical Study

Indispensable Findings from Phase 2 FELIX Study, Crucial for Obe-cel's Progress in Adult r/r B-ALL

Published Wed, Apr 24 2024 2:00 PM UTC

The recent advances in B-ALL research were vividly highlighted at the American Society of Clinical Oncology (ASCO), where a Pivotal Phase 2 FELIX study s longer-term follow-up and additional data analysis for obe-cel were selected for oral presentation. The researchers conducted this study to treat adults with relapsed/refractory B-ALL (r/r B-ALL), proclaiming significant re...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.12
Price to Sales (Expected) -
Price to Book 8.04
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.93
Working Capital Ratio 4.89
Leverage Ratio (MRQ) 5.59
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.06 $
Revenues (TTM) 0.44 $
Cash Flow (TTM) 0.03 $
Cash 0.76 $
Book Value 0.28 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 155,690
Net Income per Employee (TTM) -371,564
Receivable Turnover Ratio (TTM) 3.65
Inventory Turnover Ratio (TTM) 8.08
Asset Turnover Ratio (TTM) 0.21

Profitability Ratios Current
Gross Margin (MRQ) 55.2 %
Operating Margin (MRQ) -95.95 %
Net Margin (MRQ) -85.6 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Autolus Therapeutics Plc's Segments
Product    157.35 % of total Revenue
License    0.04 % of total Revenue
Reportable    157.38 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.